Showing 305–320 of 398 items from the last 14 days
BHP (ASX:BHP,NYSE:BHP,LSE:BHP) and MIT spin-out SiTration announced the launch of a pilot program in Arizona to extract copper from legacy mining wastewater. SiTration’s process previously demonstrated the ability to yield London Metal Exchange (LME) Grade A copper in bench-scale testing without using chemicals or generating new waste, operating at an energy consumption below 3 to 4 kilowatt-hours per kilogram. The initiative, located at BHP’s Copper Cities facility in the Globe-Miami mining district, begins with a one-month trial testing continuous, autonomous copper recovery. A second phase planned for later this year will seek to produce up to two tons of commercial-scale copper cathodes over a two-month period. The historic Copper Cities mine produced nearly 400,000 tons of copper between 1954 and 1975, with leaching operations continuing until 1982. Today, BHP manages the site under its Legacy Assets portfolio. “The Copper Cities pilot provides an opportunity to evaluate an innovative approach to recover copper from mining-impacted water while generating valuable technical and operational insights,” Kevin Ramsay, General Manager of Legacy Assets at BHP, said. Global commodity markets face supply constraints while demand surges for power grid expansion and AI data centers. Industry projections indicate annual global copper demand will rise from 34 million tons currently to 50 million tons by 2050. “The American Southwest houses legacy mining water containing billions of dollars’ worth of copper,” SiTration CEO and Co-founder Brendan Smith said in a separate press release. “With global copper demand projected to grow by around 70% by 2050 to support the rapid buildout of energy infrastructure and data centers, tapping into these resources is an excellent pathway to bolster domestic supply chains while producing copper at the bottom of the global cost curve.” For BHP, testing low-cost extraction technologies furthers its internal shift toward copper-driven expansion. In its latest financial results, copper overtook iron ore as the company's primary profit driver for the first time on an annual basis. Profits from BHP’s copper division surged 48 percent to US$18 billion, accounting for 54 percent of its US$33 billion in total underlying earnings before interest, taxation, depreciation, and amortization. “Copper is the engine that is driving BHP’s growth,” CEO Brandon Craig said during the earnings presentation. Don't forget to follow us @INN_Resource for real-time updates! Securities Disclosure: I, Giann Liguid, hold no direct investment interest in any company mentioned in this article.
Read original →Nvidia servers with Vera Rubin and Grace Blackwell chips are set to cost about 15 percent more due to an ongoing DRAM shortage from Samsung, SK Hynix, and Micron, Bloomberg reports. The price hikes hit cloud giants like Microsoft, Google, and Meta, which are pouring billions into AI infrastructure while bankrolling the market power of the very supplier they're trying to break free from. The article Memory shortage reportedly drives Nvidia AI server prices up about 15 percent appeared first on The Decoder.
Read original →Nvidia's most powerful desktop offering, the GB300 DGX Station, is available to buy starting from just $94,930 and you can spec it up to $108,350. It offers 748GB of unified memory shared across the 72-core Grace CPU and Blackwell Ultra GPU, and it can be yours in a pretty standard-looking desktop chassis today.
Read original →The chipmaker has told some of its largest customers that the prices of servers containing its AI chips could move more than 15% higher, Bloomberg News reported.
Read original →Anthropic's strict access controls against China, from geoblocking to selfie verification, are being systematically bypassed through a thriving network of so-called "transfer stations." Chinese developers can buy Claude tokens for as little as ten percent of the list price. Analyst Zilan Qian warns that the circumvention infrastructure weakens export controls and Anthropic's own safety systems. The article How China's gray market sells Claude tokens at a fraction of the price appeared first on The Decoder.
Read original →A 113GB GTA VI ISO file is circulating on the internet, with its file name making it seem like it was the game build that Cyberleek is allegedly in possession of. But upon further investigation, it appears to just be a 50KB virus padded with zeroes to make it look like the real thing.
Read original →President Donald Trump disclosed just over 1,000 financial transactions in the month of June in what appears to be broad reshuffling of his portfolio.
Read original →AI promises a total overhaul of healthcare, but for investors, turning clinical breakthroughs into actual financial returns is a long, capital-intensive game. The current landscape presents high-risk, long-horizon moonshots like humanoid surgical robotics and synthetic genomics that stand in stark contrast to immediate, high-margin software plays like clinical trial acceleration and emergency diagnostics. Here, the Investing News Network analyzes four distinct verticals currently transforming healthcare. Diagnostic & screening platforms: Unlocking high-margin leverage Next-generation liquid biopsies and multi-marker bio-AI platforms are unlocking new markets by changing how conditions like cancer and stroke are detected and treated. Innovation is redefining treatment from late-stage crisis management and toward early-stage non-invasive diagnostic platforms. Tokyo-based bio-AI company Craif uses urinary microRNA to identify pancreatic cancer at significantly earlier stages than standard blood markers permit. Because traditional blood tests frequently miss early-stage pancreatic cancer, treatment options are often severely restricted by the time a diagnosis occurs. To scale its technology, Craif recently closed a Series D funding round, raising approximately US$33 million and bringing its total capital raised to roughly US$88 million. The company is expanding its footprint in the US market through its subsidiary, Craif USA. In a press release, Craif said it plans to use the proceeds to scale R&D at its newly opened San Diego laboratory, including a prospective clinical study of its urine-based test in pancreatic cancer. Nick Bevins, MD, PhD, a physician and clinical pathology expert who has led the development and execution of clinical development strategies at multiple US life science companies, will lead the initiative as chief medical officer. AI-powered diagnostic software could also create clinical leverage in acute emergency settings. A two-year study published in the "American Journal of Neuroradiology" evaluated over 1,500 real-world emergency room stroke alerts to compare two leading platforms, RapidAI and Viz.ai. Both use AI to automatically analyze CT scans and alert medical teams of large vessel occlusion (LVO), a major blood clot blocking a main artery in the brain that can lead to severe strokes. In these cases, rapid diagnosis is critical to preventing permanent brain tissue loss. RapidAI detected 144 out of 147 confirmed clots for a 98 percent sensitivity rate while correctly clearing 94 percent of normal non-LVO scans. Viz.ai detected 108 out of 147 confirmed clots for a 73.5 percent sensitivity rate while correctly clearing 91 percent of normal non-LVO scans. “Trust in clinical AI isn’t built by a vendor’s spec sheet. It’s built on rigorous clinical validation and independent, peer-reviewed evidence demonstrating how technology performs in real-world practice,” the RapidAI team said in a press release. “The publication of the DUEL study in AJNR adds another important layer of evidence for hospitals evaluating AI solutions.” Operational AI & clinical trial acceleration: Immediate high-margin ROI Current developments highlight how technology is reshaping healthcare economics. A study conducted by the Tufts Center for the Study of Drug Development (CSDD) alongside digital trial platform Medable AI illustrates how operational AI agents offer immediate software economics by solving the high-cost, time-sensitive bottlenecks of drug development. According to the study, AI clinical monitoring agents slash Phase 3 trial operating costs by US$5.6 million per study while accelerating development timelines by 10 to 18 weeks. For Phase 2 trials, operating expenses drop by an estimated US$4.4 million per study. For large pharmaceutical sponsors managing multi-indication cancer therapies, the Tufts expected net present value model projects an 82x return on investment in Phase 3 oncology programs, generating cumulative net present value gains of up to US$565 million. These near-term operational efficiencies in clinical trials run parallel to long-horizon deep-tech developments that aim to redefine the underlying chemistry of drug discovery. Business/academic partnerships like Toronto’s quantum computing firm Xanadu Quantum Technologies' (TSE:XNDU,NASDAQ:XNDU) recent collaboration with the University of Alberta are bridging high-performance algorithms with therapeutic research. The academic-industry project aims to design next-generation photosensitizers using Xanadu’s quantum computing framework. These light-reactive molecules are used in photodynamic therapy, a non-invasive treatment that selectively destroys tumor cells without traditional side effects. This initiative marks Xanadu’s second academic partnership within a single month, following an agreement with the University of Guelph focused on workforce development. Major pharmaceutical players are taking a distinctly capital-intensive approach to long-term R&D, with Amgen (NASDAQ:AMGN), Eli Lilly (NYSE:LLY) and Johnson & Johnson (NYSE:JNJ) investing in deep-tech computing infrastructures and hybrid physics models to simulate complex biology at scale. Embodied AI & robotics: The next super-cycle As artificial intelligence transitions from software interfaces to real-world environments, embodied AI is set to catalyze a major super-cycle in high-barrier healthcare infrastructure. In July, researchers at the University of California San Diego successfully performed the world’s first live surgeries using teleoperated humanoid robots. The preclinical trial involved 5-foot-tall humanoids nicknamed “Surgie” or “Sergy” completing laparoscopic gallbladder removals on live nonprimate mammals. Researchers tested three distinct setups during the trial, which took place at the University of California San Diego's Center for the Future of Surgery, to demonstrate how humanoid robots can fit into different roles inside an operating room. In one scenario, human surgeons fully teleoperated the robots, which mirrored the surgeons’ precise hand and wrist movements in real-time. In another setup, a single humanoid worked directly alongside a physically present human surgeon, while in a more advanced setup, two humanoids operated side-by-side to complete the entire surgery with no humans standing at the operating table. This landmark demonstration highlights how embodied AI hardware-software integration will eventually transition from controlled research floors into mainstream clinical infrastructure. AI-designed phages show real-world viability The ability to design functional biology on demand reshapes both therapeutic development and global biosecurity discussions. Moving beyond single-protein prediction models like AlphaFold, researchers at Stanford University and the Arc Institute recently demonstrated that AI can generate complete multi-gene DNA blueprints for entire living organisms. Using a genomic language model named Evo, scientists generated novel functional genomes for bacteriophages, specialized viruses that infect and destroy bacteria. From these computational designs, 16 synthetic phages proved to be fully viable in laboratory testing, successfully assembling, infecting target E. coli bacteria and replicating. Several generated phages exhibited biological features unseen in natural evolution, such as incorporating structural machinery from evolutionarily distant organisms or replicating faster than wild variants. When target bacteria mutated to develop immunity against natural viral attacks, researchers deployed a custom “cocktail” of AI-designed phages that successfully bypassed host defenses and eliminated the resistant strains. This breakthrough points toward programmable biological medicines capable of evolving in real time to defeat antibiotic-resistant infections. “Evo puts the genomes of whole lifeforms within reach and accelerates the bioengineering design process... Being both multimodal and multiscale, it gives us a unified approach for harnessing the immense complexity of living systems,” said Dr. Brian Hie, assistant professor of chemical engineering at Stanford and the study’s lead researcher. Moving from digital prediction to generating functional biological entities has amplified debates surrounding dual-use risks, specifically whether generative models could eventually be adapted to design human pathogens or evade existing security protocols. “The ability to compose viral genomes using generative AI now exists; the governance to safely steer it does not. Although this is promising for life sciences applications, it also raises urgent biosafety and biosecurity questions,” doctors from the Johns Hopkins Center for Health Security said in a joint statement following the release of the study’s findings. “The question is no longer whether generative viral genome design will exist - it is whether society can build oversight that allows its benefits to unfold while preventing it from enabling serious harm.” Addressing the delicate balance between open science and biosecurity, study co-author and Stanford bioengineering researcher Samuel King emphasized the intentional boundary lines set during development, deliberately training the model on non-pathogenic architectures. Takeaway Ultimately, the maturation of AI in healthcare represents a bifurcation in investment strategy: immediate value can be captured through operational software efficiencies and diagnostic precision, while long-term capital allocation must target the heavy infrastructure of robotics and the foundational shifts in synthetic biology. As these technologies migrate from the lab to the bedside, the winners will be those who balance rapid clinical adoption with the requisite safety and governance frameworks. Navigating this landscape requires a disciplined focus on both the measurable ROI of current AI agents and the high-barrier, transformative potential of next-generation physical and genomic systems. Don’t forget to follow us @INN_Lifescience for real-time news updates! Securities Disclosure: I, Meagen Seatter, hold no direct investment interest in any company mentioned in this article.
Read original →If you're not happy with the algorithm on your Discover page, you'll love this new feature.
Read original →Walmart’s clearance aisle delivers another remarkable GPU bargain, with a shopper finding a PNY RTX 5080 for nearly half its current retail price.
Read original →Judge Yvonne Gonzalez Rogers has presided over a series of landmark tech trials and is now overseeing a case that could have a huge impact on Meta's future.
Read original →Gold prices could surge past Goldman Sachs's $4 900 year-end forecast, as surging demand for bullish gold options may amplify further gains, the bank said in a note on Friday. The bank said a further pickup in Western investor demand, combined with continued strong central bank buying, could push bullion toward key option strike levels, where dealer hedging may mechanically accelerate price moves.
Read original →A Coddy Developer Survey found that 80% of developers experience AI coding as addictive rather than helpful, triggering a new form of burnout. This behavioral pattern signals potential productivity risks and retention challenges in software development teams relying on AI-assisted tools.
Read original →The Soufan Center's July IntelBrief documented hundreds of threatening posts targeting officials over AI data center projects between July 2025 and July 2026, with volume surging in April, prompting more than 500 towns to restrict builds and councils to shutter public comment. Community opposition is creating material permitting delays and site-selection constraints for AI infrastructure deployment.
Read original →Berkshire Hathaway CEO Greg Abel is deferring equity investment decisions to Warren Buffett and portfolio manager Ted Weschler rather than directing strategy himself. This power distribution affects capital allocation strategy and signals continuity of Buffett-era stock-picking discipline despite leadership transition.
Read original →London-listed Galileo Resources and partner Statunga Investments maintain their 75%/25% joint venture stake in Zambia's Luansobe copper project (licences 34543/HQ/SML and 34545/HQ/SML) and are pursuing ownership disputes through legal channels. Unresolved title disputes delay copper development in a region where supply chain security is increasingly material to EV and renewable energy sectors.
Read original →
DailySand